Clinical trials: Measles Infection
Measles/Rubella
Freeze-dried Live Attenuated Measles/Rubella Combined Vaccine (Schwarz FF-8 Strain/TO-336 Strain) Specified Drug-use Survey of Vaccinees After the Second Vaccination
The purpose of this survey is to assess the safety of freeze-dried live attenuated measles and rubella combined vaccine (Schwarz FF-8 strain/TO-336 strain) (freeze-dried live attenuated measles and rubella combined vaccine…
- Trial name
- NCT02158364
- Testing
- Freeze-dried live attenuated measles and rubella combined vaccine (Schwarz FF-8 strain/TO-336 strain)
- Where
- Japan
- Volunteers
- 3,331 people
- Sponsor
- Takeda
Measles, Mumps
Safety Study of ProQuad® rHA in Infants (V221-037)
Primary objective: To describe the safety profile of a second dose of ProQuad® manufactured with recombinant human albumin (rHA) when administered to children in their second year of life.
- Conditions
- Measles, Mumps, Rubella, Varicella
- Trial name
- NCT00560755
- Testing
- ProQuad®
- Volunteers
- 3,388 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Encephalitis, Japanese, Measles
Immunogenicity and Safety of Japanese Encephalitis Vaccine When Given With Measles-Mumps-Rubella (MMR) Vaccine
This study aims to provide evidence that co-administration of measles-mumps-rubella vaccine (MMR) and live attenuated SA 14-14-2 Japanese encephalitis vaccine (CD-JEV) does not adversely affect immunogenicity or safety.
- Conditions
- Encephalitis, Japanese, Measles, Mumps, Rubella
- Trial name
- NCT02880865
- Testing
- Live attenuated SA 14-14-2 Japanese Encephalitis vaccine, Measles, mumps, rubella vaccine
- Where
- Philippines
- Volunteers
- 628 people, healthy volunteers welcome
- Sponsor
- PATH
Rubella, Mumps
Immunogenicity and Safety of GSK Biologicals' Combined Measles-mumps-rubella Vaccine in Volunteers, Seven Years of Age and Older
The purpose of this study is to evaluate the immunogenicity and safety of GSK's trivalent MMR (Priorix®), comparing it to Merck"s MMR vaccine (M-M-R®II), which is approved for use in the US.
- Conditions
- Rubella, Mumps, Measles
- Trial name
- NCT02058563
- Testing
- Priorix®, Merck's M-M-R®II, Measles, Mumps, and Rubella Virus Vaccine
- Where
- 17 sites in United States, Estonia and 1 more
- Volunteers
- 996 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Prophylaxis for the Measles Infection
A Clinical Trial to Assess the Safety of a Measles Vaccine (Dry Powder) Administered by Two Different Devices
This is a phase I, open-label, randomized study in healthy adults. Eligible subjects will be given single dose of either Dry Powdered Measles Vaccine (PMV) by Puffhaler® device, Dry PMV by SoloventTM device or licensed measles…
- Trial name
- PMV-001 (NCT01557699)
- Testing
- PMV via Puffhaler® device, PMV via SoloventTM device, Licensed Subcutaneous Measles Vaccine
- Where
- India
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Serum Institute of India Pvt. Ltd.
Varicella, Measles
Immunogenicity and Safety Study of Proquad® and Infanrix® Hexa When Administered Concomitantly (V221-035)
Primary Objective: To demonstrate that ProQuad® can be administered concomitantly with a booster dose of Infanrix® hexa to healthy children 12 to 23 months of age without impairing either the antibody response rates to measles…
- Conditions
- Varicella, Measles, Mumps, Rubella
- Trial name
- NCT00432042
- Testing
- ProQuad®, Infanrix® hexa
- Where
- 50 sites in Germany, Italy
- Volunteers
- 955 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Chikungunya Virus Infection
Chikungunya Vaccine (V184) Study in Previously Exposed Adults (V184-006)
Safety and immunogenicity of the investigational V184 chikungunya vaccine will be tested in participants with history of chikungunya infection.
- Trial name
- NCT03807843
- Testing
- V184
- Where
- Puerto Rico
- Volunteers
- 41 people, healthy volunteers welcome
- Sponsor
- Themis Bioscience GmbH
Measles-Mumps-Rubella
Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Combined Measles-mumps-rubella (MMR) Vaccine in Subjects Four to Six Years of Age
The purpose of this study is to support licensure of GSK Biologicals' MMR vaccine (Priorix®) in the US by generating immunogenicity and safety data in contrast to the US standard of care, Merck's MMR vaccine (M-M-R®II), when…
- Trial name
- NCT01621802
- Testing
- Priorix, M-M-R II, Kinrix
- Where
- 67 sites in United States, South Korea and 1 more
- Volunteers
- 4,011 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline